GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » C4X Discovery Holdings PLC (FRA:C4J) » Definitions » EPS (Diluted)

C4X Discovery Holdings (FRA:C4J) EPS (Diluted) : €0.05 (TTM As of Jan. 2024)


View and export this data going back to 2020. Start your Free Trial

What is C4X Discovery Holdings EPS (Diluted)?

C4X Discovery Holdings's Earnings per Share (Diluted) for the six months ended in Jan. 2024 was €0.08. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 was €0.05.

C4X Discovery Holdings's EPS (Basic) for the six months ended in Jan. 2024 was €0.08. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jan. 2024 was €0.05.

C4X Discovery Holdings's EPS without NRI for the six months ended in Jan. 2024 was €0.08. Its EPS without NRI for the trailing twelve months (TTM) ended in Jan. 2024 was €0.05.

During the past 3 years, the average EPS without NRIGrowth Rate was 18.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 8.50% per year. During the past 10 years, the average EPS without NRI Growth Rate was 0.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 12 years, C4X Discovery Holdings's highest 3-Year average EPS without NRI Growth Rate was 42.40% per year. The lowest was -122.80% per year. And the median was 4.60% per year.


C4X Discovery Holdings EPS (Diluted) Historical Data

The historical data trend for C4X Discovery Holdings's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C4X Discovery Holdings EPS (Diluted) Chart

C4X Discovery Holdings Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 -0.09 -0.02 -0.04 -0.05

C4X Discovery Holdings Semi-Annual Data
Jul14 Jan15 Jul15 Jan16 Jul16 Jan17 Jul17 Jan18 Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23 Jan24
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.03 0.08

Competitive Comparison of C4X Discovery Holdings's EPS (Diluted)

For the Biotechnology subindustry, C4X Discovery Holdings's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C4X Discovery Holdings's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, C4X Discovery Holdings's PE Ratio distribution charts can be found below:

* The bar in red indicates where C4X Discovery Holdings's PE Ratio falls into.



C4X Discovery Holdings EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

C4X Discovery Holdings's Diluted EPS for the fiscal year that ended in Jul. 2023 is calculated as

Diluted EPS (A: Jul. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-12.944-0)/251.958
=-0.05

C4X Discovery Holdings's Diluted EPS for the quarter that ended in Jan. 2024 is calculated as

Diluted EPS (Q: Jan. 2024 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(20.761-0)/252.202
=0.08

EPS (Diluted) for the trailing twelve months (TTM) ended in Jan. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C4X Discovery Holdings  (FRA:C4J) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


C4X Discovery Holdings EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of C4X Discovery Holdings's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


C4X Discovery Holdings (FRA:C4J) Business Description

Traded in Other Exchanges
Address
53 Portland Street, Manchester One, Manchester, GBR, M1 3LD
C4X Discovery Holdings PLC is a drug discovery and development company. It has various proprietary and synergistic software platforms Taxonomy3, Conformetrix, and 4Sight. Taxonomy3 is a novel in silico platform technology that utilizes proprietary ground-breaking mathematical algorithms to perform complex multivariate analysis of genetic data. Conformetrix enables rational, accelerated 4D structural drug design using experimental data rather than theoretical data. The 4Sight allows its research scientists to view, understand and interrogate the complex, multidimensional molecular shape data of drug molecules.

C4X Discovery Holdings (FRA:C4J) Headlines

No Headlines